VivoSeq
Oncology

Biliary Tract Tumors

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Biliary Tract Tumors is an early-stage landscape with 0 programs across 2 companies. The most active players are CellAct Pharma GmbH, BioNTech.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

CellAct Pharma GmbH

0 programs

PreclinicalBioNTech logo

BioNTech

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting2 · 40%
Terminated2 · 40%
Unknown status1 · 20%

Clinical Trials

Trial Activity

QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
Recruiting·—·Phase 2·NCT06892925·59 enrolled
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05291052·20 enrolled
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06620848·49 enrolled
CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors
Terminated·CCellAct Pharma GmbH·Phase 2·NCT02094560·45 enrolled
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Terminated·BioNTech logoBioNTech·Phase 1/2·NCT04683939·13 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)